Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3440 - Phase I dose of oral quisinostat, in combination with gemcitabine (G) and cisplatin (Cis) or paclitaxel (P) and carboplatin (Carbo) in patients (pts) with non-small cell lung cancer or ovarian cancer (OC)

Date

10 Oct 2016

Session

Poster display

Presenters

Mikhail Fedyanin

Citation

Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368

Authors

M. Fedyanin1, S. Tjulandin2, S. Cheporov3, V. Vladimirov4, V. Moiseenko5, S. Orlov6, G. Manikhas7, A. Cakana8, V. Azarova9, O. Karavaeva9, N. Vostokova9, S. Baranovskiy9

Author affiliations

  • 1 Clinical Pharmacology And Chemotherapy, Russian Oncology Research Center named after Blokhin N.N., 115478 - Moscow/RU
  • 2 Clinical Pharmacology And Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 3 Chemotherapy, State "Regional Clinical Oncology Hospital" health care institution of Yaroslavl region, 150054 - Yaroslavl/RU
  • 4 Chemotherapy Outpatient Departament, Pyatigorsk Affiliate of Stavropol Regional Oncology Center, 357500 - Pyatigorsk/RU
  • 5 Chemotherapy, GBUZ Saint-Petersburg clinical scientific and practical center special kinds of medical care (oncology), 197758 - Saint Petersburg/RU
  • 6 Bioeq, LLC, 197342 - Saint Petersburg/RU
  • 7 Department Of Gynaecological Oncology, Saint-Petersburg State Budget institution Healthcare Municipal Clinical Oncology Dispensary, 197022 - Saint Petersburg/RU
  • 8 Janssen Pharmaceutica N.v., Janssen Pharmaceutica N.V., HP12 4EG - High Wycombe/GB
  • 9 Ipharma, LLC, 143026 - Moscow/RU
More

Resources

Abstract 3440

Background

The mechanism of action of quisinostat (Q) includes protein acetylation, leading to re-activation of tumor suppressor genes and restoration of tumor sensitivity to chemotherapy

Methods

The primary endpoint was to identify the maximum tolerated dose (MTD) of Q. Secondary endpoints included safety, overall response rate, and pharmacokinetics parameters. Q was administered orally at escalated doses (8, 10 and 12 mg); 3 week cycle on Days 1, 3, 5, 7, 9, 11. In the 1st arm NSCLC pts received Q with G (1000 mg/m2) on Day 7 and 14 and Cis (75 mg/m2) on Day 7 of each cycle, for 2nd line. If Q was deemed tolerable at 12 mg, another dosage cohort was to have been started: Q (12 mg) with G (1250 mg/m2) on Days 7 and 14 and Cis (75 mg/m2) on Day 7 of each cycle for 1st line NSCLC. In the 2nd arm pts received Q with P (175 mg/m2) and Carbo (AUC5) on Day 7 of each cycle, in 2nd or subsequent lines for pts with NSCLC or OC. Dose escalation was according to the “3 + 3” dose-limiting toxicity (DLT) algorithm. After definition of MTD, additional pts were to have been included

Results

51 pts (QGCis – 28 pts, QPCarbo – 23 pts; NCSLC – 33 pts, OC – 18 pts) were enrolled: 49% male; median age = 59.6 (range 40-74) years. There were no DLTs. Q was tolerated to the maximum dose of 12 mg chosen for this study, and therefore there were MTD criteria never met; Q at 12 mg in combo was chosen and is dose recommended for Phase 2 development. The most common adverse events (AE) were neutropenia - 56% and 57%, thrombocytopenia - 39% and 75%, anemia - 35% and 64% for group of QPCarbo and QGCis, respectively. Any serious AE were revealed in 21.6% pts, Q related serious AE – in 13.7%, AE ¾ grades – in 64.7%, and 23.5% pts discontinued therapy due to AE. 46 pts were evaluable for response, with responses observed in 8 (17%): 8 PRs (NSCLC: 2/30 pts, 6.7%; OC: 6/16 pts, 37.5%). Most pts with OC with partial response had platinum resistance relapses

Conclusions

On successfully completing the trial, the recommended dose of Q for phase 2 study is 12 mg in combination with G 1250 mg/m2) and Cis (75 mg/m2) or P (175 mg/m2) and Carbo (AUC5). The combination QPCarbo showed activity in the treatment of pts with platinum resistant OC

Clinical trial identification

NCT02728492

Legal entity responsible for the study

N/A

Funding

NewVac

Disclosure

M. Fedyanin: consultant of NewVac. S. Orlov: Employment - BioEq, LLC. A. Cakana: Employment - Janssen Pharmaceutica N.V. V. Azarova, O. Karavaeva, N. Vostokova: Employment - IPHARMA, LLC S. Baranovskiy: Employment – NewVac. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings